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Abstract
Background:  The physiological regulation of G protein-coupled receptors, through
desensitization and internalization, modulates the length of the receptor signal and may influence
the development of tolerance and dependence in response to chronic drug treatment. To explore
the importance of receptor regulation, we engineered a series of Gi-coupled receptors that differ
in signal length, degree of agonist-induced internalization, and ability to induce adenylyl cyclase
superactivation. All of these receptors, based on the kappa opioid receptor, were modified to be
receptors activated solely by synthetic ligands (RASSLs). This modification allows us to compare
receptors that have the same ligands and effectors, but differ only in desensitization and
internalization.
Results: Removal of phosphorylation sites in the C-terminus of the RASSL resulted in a mutant
that was resistant to internalization and less prone to desensitization. Replacement of the C-
terminus of the RASSL with the corresponding portion of the mu opioid receptor eliminated the
induction of AC superactivation, without disrupting agonist-induced desensitization or
internalization. Surprisingly, removal of phosphorylation sites from this chimera resulted in a
receptor that is constitutively internalized, even in the absence of agonist. However, the receptor
still signals and desensitizes in response to agonist, indicating normal G-protein coupling and partial
membrane expression.
Conclusions:  These studies reveal that internalization, desensitization and adenylyl cyclase
superactivation, all processes that decrease chronic Gi-receptor signals, are independently
regulated. Furthermore, specific mutations can radically alter superactivation or internalization
without affecting the efficacy of acute Gi signaling. These mutant RASSLs will be useful for further
elucidating the temporal dynamics of the signaling of G protein-coupled receptors in vitro and in vivo.
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Background
The specificity, diversity, and physiological importance of
G protein-coupled receptors (GPCR) have made these
receptors excellent drug targets. It is becoming clear that
the regulation of the GPCR itself – its location, stability,
and signal duration – is a key component of the signaling
process [1,2] The length of a GPCR signal can be modu-
lated by receptor desensitization (decrease in receptor
responsiveness) and receptor internalization (trafficking
of receptors to endocytotic vesicles). The cell can also
respond to prolonged activation by upregulating compen-
satory pathways. For example, prolonged signaling
through a Gi-coupled receptor inhibits adenylyl cyclase
(AC), while paradoxically increasing the ability of the Gs-
coupled pathway to stimulate AC, a phenomenon known
as AC superactivation [3]. Such regulatory mechanisms
may contribute to the development of drug tolerance and
dependence, including the response to chronic opiate use
[4].
The complex effects of drugs at multiple receptor subtypes
in multiple tissues have made it difficult to isolate the rel-
ative contributions of GPCR regulation, ligand binding,
effector coupling, drug metabolism, and cellular down-
regulation machinery. Even if two receptors couple to the
same signaling pathway, the physiological effects of their
activation could vary tremendously depending on the
pharmacokinetics of the ligands, the cell type expressing
the receptors, and the interactions with desensitization
mechanisms. An engineered family of receptors that share
the same ligand binding and effector coupling, yet have
discrete mutations that cause them to internalize or
desensitize differentially, would help pinpoint the physi-
ological consequences of GPCR desensitization. This is
especially important in the light of recent evidence show-
ing dramatically different endocytosis and signaling pro-
files of mu opioid receptors (MOR) in response to
different ligands [5,6]. In addition, understanding the sig-
nals that allow transmembrane proteins to be more or less
resistant to endocytosis will improve our understanding
of endocytosis as a general regulatory mechanism, as it
has been implicated in the regulation of signaling of
growth factor receptors [7,8] and ion channels [9-11].
Our laboratory has engineered a Gi-coupled receptor that
is insensitive to endogenous ligands but can still respond
to the synthetic small-molecule agonist spiradoline
[12,13]. This receptor activated solely by a synthetic lig-
and (RASSL) was based on the kappa opioid receptor
(KOR). In the original RASSLs, exchanging the second
extracellular loop of the KOR with the corresponding
sequence from the delta opioid receptor, and making an
additional point mutation (Q297E), resulted in a receptor
with 1/2,000 of the response to dynorphin and other
endogenous peptides relative to the wild-type KOR. How-
ever, the response of this RASSL to spiradoline was not
altered. RASSLs can be expressed in a tissue-specific man-
ner in transgenic mice, allowing direct control of Gi-medi-
ated physiological responses such as heart rate [14]. It has
also been recently used to help identify the mammalian
sweet receptor by expressing it in mouse taste buds [15].
To investigate the endocytosis and desensitization of
GPCRs, we have since developed four new RASSLs. To vis-
ualize these RASSLs in living cells, we fused the green flu-
orescent protein (GFP) to the N-terminus (outer portion)
of the RASSL resulting in Rog (RASSL opioid green). Given
the well-documented role of the C-terminal region in the
desensitization and internalization of GPCRs [1,16-18],
we made a series of C-terminal mutant RASSLs designed
to desensitize and internalize at different rates.
This novel receptor system offers an opportunity to test
specific hypotheses about the relationship between recep-
tor sequence and receptor regulation, without requiring
the use of multiple ligands that might have different
effects on the signal and the regulation of receptors.
Because RASSLs lack endogenous agonists, they allow
greater control of the timing and specificity of activation
than is possible with endogenous receptors. In these stud-
ies, we test how the removal of phosphorylation sites
from the C-terminal regions of a Gi-coupled RASSL alters
the receptor's internalization, desensitization, and induc-
tion of AC superactivation. Since it is well established that
the endogenous mu and kappa opioid receptors differ in
these properties, we also explore the regulation of kappa
opioid RASSLs bearing specific portions of the mu opioid
receptor C-terminal sequence. The cell culture experi-
ments presented here provide a basis for in vivo studies in
complex tissues such as the nervous system. Insight
gained through these experiments may help explain the
differences seen in vivo between different endogenous Gi-
coupled receptors, improving our understanding of the
contribution of receptor regulation to the physiological
response to agonists and our overall understanding of
GPCR signal regulation.
Results
Rog, a GFP-tagged RASSL, signals appropriately
Although an N-terminal GFP tag does not interfere with
the function of the human KOR [19], we wanted to con-
firm that this tag does not modify the signaling properties
of Rog, a KOR-based RASSL. Rog was transiently trans-
fected into CHO cells along with a chimeric Gqi5 protein
[20] that couples to Gi-coupled receptors but signals
through the Gq pathway and therefore stimulates calcium
release. Using this transient calcium response as a meas-
ure of Gi activation, we showed by FLIPR assay that Rog
responded dose-dependently to spiradoline, but not to a
range of doses of dynorphin, the endogenous ligand that
activates the wild-type KOR (Figure 2A). Therefore, Rog,BMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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Agonist-induced signaling and internalization of Rog Figure 2
Agonist-induced signaling and internalization of Rog. (A) Maximum calcium response plotted as a function of spirado-
line dose for cells transfected with Rog or the wild-type KOR and treated with dynorphin or spiradoline. (B) Confocal micro-
graphs show representative internalization of GFP-tagged Rog receptors 1 h after treatment with 10 µM or 100 µM 
spiradoline. Dynorphin at 100 µM (far right) caused little internalization in this assay. (C) ELISA for FLAG-tagged cell-surface 
receptors shows dose-dependent loss of receptors from cell surface one h after spiradoline treatment. After a 1 µM dose of 
spiradoline, internalization is evident within 15 minutes. Data are expressed as a percentage of receptors detected on surface 
of untreated cells expressing Rog. Error bars represent SEM for three replicates.BMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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like its predecessors Ro1 and Ro2 [12], meets the criteria
for a RASSL.
We evaluated all of the engineered receptors for their abil-
ity to affect cAMP formation. Gi signaling decreases intra-
cellular cAMP levels by directly inhibiting adenylyl
cyclase. Activation of these Gi-coupled receptors with
spiradoline was therefore expected to inhibit forskolin-
induced cAMP accumulation in a dose-dependent man-
ner. Indeed, under basal conditions, 15-min treatment
with spiradoline activated Rog, Rog-A, Rog-µ and Rog-µA,
as indicated by inhibition of forskolin-induced accumula-
tion of cAMP (Figure 5, Table 1). Despite differences in C-
terminal amino acid sequence, the RASSLs showed no sig-
nificant differences in their ability to inhibit cAMP accu-
mulation after acute activation with spiradoline (Table 1).
EC50 and cAMP inhibition values for all of the RASSLs
were similar to those seen with the human KOR in the
same assay. In a representative experiment, the EC50 for
KOR was 0.91 nM spiradoline and cAMP inhibition was
68.6%.
Rog is internalized by agonist treatment
The GFP tag on Rog allows direct observation of agonist-
induced receptor internalization by confocal microscopy
(Figure 2B). In untreated cells, the receptor was visible pri-
marily on the plasma membrane. One hour after spirado-
line treatment (10–100 µM), the receptor was observed in
bright, punctate intracellular vesicles. Dynorphin (100
µM), in contrast, did not lead to significant internaliza-
tion of the receptor (Figure 2B). An ELISA that detects only
cell-surface receptors was used to quantify the extent of
receptor internalization after spiradoline treatment. With
increasing doses of spiradoline, fewer receptors were
detected on the cell surface, culminating in an approxi-
mately 45% loss of cell-surface receptors at the maximal
dose of 100 µM (Figure 2C). The same dose of spiradoline
resulted in a similar 47% loss of KOR from the cell surface
(not shown). The time course of internalization in
response to 1 µM spiradoline was relatively rapid, with
significant receptor loss apparent within 5 min (Figure
2C). Maximal receptor loss was detected approximately
20 min after agonist treatment began.
Rog-A is resistant to agonist-induced internalization
To determine the role of C-terminal phosphorylation sites
in receptor regulation, we examined spiradoline-induced
internalization of Rog-A, a mutated version of Rog in
which four C-terminal phosphorylation sites were
mutated to alanine (Figure 1). HEK293 cells stably trans-
fected with Rog-A were treated with 10 µM spiradoline, a
dose sufficient to cause internalization of most Rog recep-
tors (Figure 3A, left). One hour after spiradoline treat-
ment, most Rog-A receptors appeared to remain in the
membrane (Figure 3A, center). Quantification by cell-sur-
face ELISA showed significantly less loss of cell-surface
receptors for Rog-A than for Rog at spiradoline doses of
0.1–100 µM (Figure 3B). ANOVA indicated a main effect
of drug dose (F10,20 = 66.53, p < 0.0001) and a main effect
of receptor type (F1,20 = 55.29, p < 0.0001). As observed
with Rog, maximal internalization of Rog-A in response to
1 µM spiradoline occurred after 20 min of drug treatment
(Figure 3B). However, in contrast to Rog, fewer than 10%
of the Rog-A receptors were internalized at that time
point. ANOVA of the time course data indicated a main
effect of length of treatment (F11,47 = 11.39, p < 0.0001), a
main effect of receptor type (F1,47 = 203.16, p < 0.0001),
and an interaction between receptor type and treatment
length (F11,47 = 2.27, p < 0.02). These results suggest that
C-terminal phosphorylation promotes receptor internali-
zation. Activation of Rog-A inhibits cAMP as fully as Rog
(Table 1), indicating that the reduced internalization does
not alter acute signaling.
Rog-µ more readily internalizes in response to spiradoline
Since the mu opioid receptor (MOR) internalizes more
readily than the KOR, we made Rog-µ, a chimeric receptor
in which the entire intracellular portion of the C-terminus
was replaced with the corresponding MOR sequence (Fig-
ure 1). Rog-µ was expected to internalize to a greater
extent than Rog in response to spiradoline. Confocal
microscopy showed nearly complete internalization of
Rog-µ after one hour of treatment with 10 µM spiradoline
(Figure 3A, right). A cell-surface ELISA revealed 25–30%
internalization of Rog-µ at low doses of spiradoline, rang-
ing from 0.01 to 0.1 µM (Figure 3C). Little internalization
of Rog or Rog-A has been observed at these doses (Figures
3B and 3C). At higher doses of spiradoline, no difference
in internalization between Rog and Rog-µ was observed.
ANOVA indicated a main effect of drug dose (F9,52 =
55.79, p < 0.0001) and an interaction between receptor
type and drug dose (F9,52 = 3.89, p < 0.0008). Post-hoc
Scheffé analysis shows significant differences between Rog
and Rog-µ at 0.01 µM (p = .024) and 0.1 µM (p = .016)
doses of spiradoline. When cells were treated with 1 µM
spiradoline for differing lengths of time, there was no
detectable difference in the time course of internalization
of Rog and Rog-µ (Figure 3C). ANOVA indicated a main
effect of time (F11,48 = 53.20, p < 0.0001), with no effect of
receptor type. There was also no difference in cAMP inhi-
bition after spiradoline activation of Rog and Rog-µ
(Table 1).
Constitutive internalization of Rog-µA
A variant of Rog-µ, known as Rog-µA, also has MOR
sequence at the C-terminus, but five serine and glutamic
acid residues at the C-terminus were mutated (Figure 1).
These mutations were predicted to render Rog-µA more
resistant to internalization than Rog-µ [18]. However, in
several independent stably and transiently transfected cellBMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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Desensitization of cAMP inhibition and superactivation of AC after pretreatment with spiradoline Figure 5
Desensitization of cAMP inhibition and superactivation of AC after pretreatment with spiradoline (A) Spirado-
line (1 nM pretreatment) inhibited forskolin-induced cAMP formation in HEK293 cells transiently expressing Rog, Rog-A, Rog-
µ, and Rog-µA. Data are expressed as inhibition of forskolin-induced cAMP. The baseline (0) represents maximum forskolin-
induced cAMP accumulation in control cells. Pretreatment with 1 nM spiradoline for 10 min causes a shift in the dose-response 
curve for later spiradoline treatment in Rog and Rog-µA cells, but not Rog-A. Spiradoline pretreatment lowered the maximal 
response of Rog-µ to subsequent spiradoline treatment. (B) HEK293 cells transiently expressing receptors were treated 18 h 
with 10 nM spiradoline, and assayed for cAMP accumulation in response to a 15-min treatment with 10 µM forskolin. Spirado-
line pretreatment significantly increased forskolin-induced cAMP in cells expressing KOR, Rog and Rog-A. Pretreatment of 
cells expressing Rog-µ and Rog-µA had not effect on response to forskolin. Data are expressed relative to the amount of 
cAMP accumulated after 10 µM forskolin treatment in cells pretreated with vehicle. Bars represent mean ± SEM for six repli-
cates per condition. (C) HEK293 cells transiently expressing receptors were treated 18 h with 10 nM spiradoline, and assayed 
for loss of cell-surface expression by ELISA. Long-term spiradoline treatment significantly reduces cell-surface expression of all 
receptors, but the degree of internalization does not differ among different receptors. Bars represent mean ± SEM for three 
replicates per condition.
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Table 1: EC50 and Emax values for inhibition of cAMP accumulation by spiradoline
Rog Rog-A Rog-µ Rog-µA
EC50 (nM spiradoline)
Acute activation 0.41 ± 0.08 0.41 ± 0.15 0.42 ± 0.23 0.50 ± 0.22
1 nM spiradoline 
pretreatment
4.32 ± 1.96 0.42 ± 0.21 2.05 ± 0.03 > 13.44 ± 5.41
% Inhibition
Acute activation 64.4 ± 4.8 56.1 ± 5.1 58.0 ± 0.9 64.1 ± 4.8
1 nM spiradoline 
pretreatment
55.7 ± 3.7 53.3 ± 0.9 43.6 ± 1.5 51.5 ± 6.0
Values are mean ± SEM for 3–8 experiments for each condition.
Design of RASSL variants Figure 1
Design of RASSL variants. The design of each RASSL variant is shown on the left. Differences in amino acid sequences of 
the receptor variants are shown in the C-terminal alignments, right. Sequence derived from the MOR are dark, while KOR 
sequences are light. All mutated residues are underlined.
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Agonist-induced internalization is reduced in Rog-A, but not Rog-µ Figure 3
Agonist-induced internalization is reduced in Rog-A, but not Rog-µ. (A) Confocal micrographs showing localization of 
GFP-tagged Rog (left), Rog-A (center), or Rog-µ (right) stably expressed in HEK293 cells and treated with 10 µM spiradoline 
for 1 h before fixation. (B) A dose-response ELISA shows less internalization of Rog-A in response to 1 h of spiradoline at 
doses of 0.3–100 µM spiradoline. After treatment with 1 µM spiradoline, Rog-A showed less internalization up to 1 h after 
treatment. (C) A dose-response ELISA shows more internalization of Rog-µ in response to 1 h of low doses of spiradoline 
ranging from 0.01 to 0.1 µM. After treatment with 1 µM spiradoline, there was no difference in the time course of internaliza-
tion between Rog and Rog-µ. ELISA data are expressed as a percentage of receptors detected on surface of untreated cells 
expressing the same receptor.BMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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Antagonist treatment increases cell-surface expression of Rog-µA Figure 4
Antagonist treatment increases cell-surface expression of Rog-µA. (A) ELISA comparing cell-surface expression of 
receptors stably expressed in HEK293 cell lines, either untreated (white bars) or treated for 18 h with the antagonist norBNI 
(10 µM, dark bars). Error bars represent SEM for three replicates. NorBNI significantly increased cell-surface expression of 
both Rog-µ and Rog-µA. OD, optical density. (B) Confocal micrographs showing that the localization of GFP-tagged Rog-µA is 
primarily intracellular in untreated cells (left), but the receptor moves to the membrane after 18 hours of antagonist treatment 
(right). There is relatively little change in Rog after norBNI treatment relative to untreated cells.BMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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lines (HEK293 and rat1a), Rog-µA always had signifi-
cantly lower cell-surface expression than other receptors.
As shown by cell-surface ELISA of one representative
group of stably transfected HEK293 lines, Rog-µA was
expressed at 28% of the level of Rog, and 41% of Rog-µ
(Figure 4A). Despite the low cell-surface expression, Rog-
µA signals as well as the other RASSLs after acute spirado-
line treatment (Table 1).
Since cell-surface expression of a GPCR can be stabilized
by the addition of antagonist [21,22], we examined the
effect of the KOR antagonist norBNI on cell-surface
expression of Rog-µA. Antagonist treatment nearly dou-
bled the amount of Rog-µA detected in the membrane
(Figure 4A; p < 0.005; F1,6 = 27.00). It also increased the
cell-surface expression of Rog-µ, but to a lesser degree (p
< 0.05, F1,6 = 11.54). In contrast, it had no effect on the
cell-surface expression of Rog. The increase in membrane
expression of Rog-µA after antagonist treatment was con-
firmed by confocal microscopy. Under basal conditions,
little Rog-µA was seen in the plasma membrane, although
the receptor was readily detected in other areas of the cell
(Figure 4B). After overnight treatment with 10 µM
norBNI, most of the Rog-µA was seen in the plasma mem-
brane (Figure 4B). In contrast, untreated Rog receptors
were primarily located in the plasma membrane (Figures
2B, 4B), and norBNI treatment had little effect on their
localization (Figure 4B). These experiments suggest that
Rog-µA may be constitutively downregulated and rapidly
cycled in and out of the plasma membrane.
Rog-A is more resistant to desensitization
In addition to regulation by internalization, a GPCR sig-
nal can be modulated by desensitization: uncoupling
from the signaling effectors after continuous agonist stim-
ulation. To explore desensitization directly, we briefly pre-
treated each RASSL with 1 nM spiradoline for 15 min, and
examined inhibition of cAMP accumulation in response
to a variety of doses of spiradoline. The low pretreatment
dose had caused no receptor internalization detectable by
ELISA-based assays. Pretreatment reduced the responsive-
ness of Rog receptors to spiradoline (Figure 5A, Table 1).
The same maximal inhibition of cAMP accumulation was
observed, but the dose response curve was shifted approx-
imately 10-fold, with the EC50 for Rog shifting from 0.41
nM to 4.32 nM spiradoline after spiradoline pretreatment.
Pretreatment of Rog-A with the same dose of spiradoline,
however, did not significantly affect the response of the
cells to subsequent treatment (Figure 5A, Table 1). The
EC50 for spiradoline after 1 nM spiradoline pretreatment
of Rog-A was 0.42 nM, compared to 0.41 nM for vehicle-
treated cells. Spiradoline pretreatment shifted the EC50 of
Rog-µ to 2.05 nM (Figure 5A, Table 1). Notably, the max-
imal response of pretreated Rog-µ-expressing cells was less
than half that of untreated cells, indicating a decreased
efficacy of Rog-µ signaling through the Gi pathway. Spira-
doline pretreatment strongly reduced the response of Rog-
µA to further spiradoline treatment (Figure 5A, Table 1).
In fact, it appears that the response to spiradoline in pre-
treated Rog-µA cells is so low that the dose range tested
(up to 100 nM) does not yield a maximal inhibition of
cAMP, and no sigmoidal dose-response curve can be fitted
to these data. Therefore, we cannot calculate an accurate
EC50 for desensitized Rog-µA receptors. However,
assuming that the maximal response occurs at doses
higher than 100 nM spiradoline, we can estimate that the
EC50 would be at least 13.44 nM. This indicates that Rog-
µ and Rog-µA receptors desensitize readily. For these
receptors, the dose of spiradoline required to achieve the
EC50 is significantly lower than the dose required to inter-
nalize the cell-surface receptors (Figures 4, 5). While only
a fraction of the total surface receptor pool needs to be
activated to activate Gi maximally, a much larger fraction
of the receptor population must be internalized before it
can be accurately measured.
AC superactivation is independent of receptor 
internalization
Chronic treatment of cells expressing Gi-coupled receptors
with agonist results in a compensatory increase in the
activity of AC and, therefore, an increased accumulation
of cAMP in response to the same dose of forskolin [3]. We
examined the development of this AC superactivation in
cell lines transiently expressing the RASSL variants. For-
skolin (10 µM) stimulates twice as much cAMP in Rog-
expressing cells treated with 10 nM spiradoline for 18
hours, compared to cells acutely treated with forskolin
alone (Figure 5B; p < 0.005, F1,10 = 17.72). A similar
degree of superactivation was seen in cells transfected
with the wild-type KOR, indicating the same cellular
response to prolonged Gi signaling through both Rog and
KOR. Overnight treatment of Rog-A-expressing cells with
spiradoline, followed by stimulation with 10 µM forsko-
lin, resulted in a slightly smaller increase in cAMP (Figure
5B; p < 0.05, F1,10 = 9.52). Notably, cells expressing Rog-µ
and Rog-µA receptors showed no evidence of AC superac-
tivation after 18 h of spiradoline pretreatment. These data
show that receptors that desensitize and internalize more
readily at the receptor level, such as Rog-µ and Rog-µA, do
not induce compensations in an opposing signaling
pathway.
Although little internalization of these RASSLs has been
observed at these low doses of spiradoline, we wanted to
ensure that the AC superactivation data could not be
explained by differences in receptor internalization.
Therefore, we performed an analysis of cell-surface recep-
tor expression in parallel with the cAMP response experi-
ment. Cells were plated and treated with 10 nM
spiradoline for 18 hours exactly as described above. ThenBMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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the cells were fixed and a cell-surface ELISA was per-
formed. In general, 7–10% of the receptors were internal-
ized by this treatment, but there were no significant
differences between receptor types (Figure 5C). ANOVA
showed a significant treatment effect (F1,18 = 8.22, p <
0.01), but no effect of receptor type (p > 0.99).
Discussion
We have engineered a series of RASSLs that inhibit cAMP
after acute activation by spiradoline with equal efficacy
but differ dramatically in cellular location and responses
to chronic drug treatment.
Mutation of phosphorylation sites on the C-terminus to
alanines resulted in a receptor that was relatively resistant
to internalization in the presence of moderate doses of
agonist (Rog-A, Figure 3) and showed no significant
desensitization after pretreatment with a low dose of ago-
nist (Figure 5A). This is consistent with recent findings
that mutation of a single serine to alanine is sufficient to
block internalization and desensitization of the KOR,
since this mutation removes a residue that is required for
G protein receptor kinase (GRK2) phosphorylation [23].
While these studies highlight the importance of GRK
phosphorylation of GPCRs in mediating receptor inter-
nalization and desensitization, it is notable that partial
internalization of Rog-A was still detected in response to
higher doses of spiradoline, indicating that the receptor
can be internalized through different mechanisms.
Reports of GPCR endocytosis in the absence of GRK phos-
phorylation [24-26] suggest that the removal of C-termi-
nal phosphorylation sites may reduce the affinity of the
receptor for proteins that mediate endocytosis without
preventing the protein-protein interactions that are essen-
tial for internalization.
Rog-µ, the MOR/KOR chimeric mutant, was more sensi-
tive to agonist-induced desensitization (Figure 5A) and
internalization (Figure 3) than Rog. This is consistent with
observations that the MOR internalizes and desensitizes
more readily than the KOR. Surprisingly, mutation of C-
terminal phosphorylation sites on the MOR/KOR chimera
to form Rog-µA did not inhibit desensitization (Figure
5A). Rog-µA has low basal surface expression, although
the GFP-tagged receptor can be seen throughout the cell
(Figure 4B). It is unlikely that the extracellular mutations
in Rog-µA are responsible for the unusual internalization
pattern of this receptor. The extracellular mutations in
Rog-µA are identical to the ones in Rog, which was shown
to reach the cell surface and respond to agonist the same
as GFP-tagged wild-type KOR (Figure 2). The intracellular
pool of Rog-µA is not due to receptor misfolding or abnor-
mal sorting, because some receptor was detected on the
membrane (Figure 4A) and the receptor showed normal
agonist-induced signaling (Figure 5A, Table 1). The obser-
vation that the addition of an antagonist can "rescue" the
low cell-surface expression of Rog-µA (Figure 4A) further
suggests that misfolding is not responsible for the
decrease in cell surface expression.
There are several potential mechanisms for the increase in
cell-surface expression after antagonist treatment. One
possibility is that the antagonist, norBNI, acts as a molec-
ular chaperone, entering the cell, binding to the receptor
in intracellular compartments, and bringing it to the
membrane. Ligands can act as pharmacological chaper-
ones for the delta opioid receptor, facilitating receptor
maturation and export from the endoplasmic reticulum
[21]. However, there are no reports that the norBNI antag-
onist is cell-permeable. Another possibility is that norBNI
acts as an inverse agonist, stabilizing cell-surface receptors
in an "off" conformation, making them inaccessible to
GRKs and arrestins, which usually interact only with
active receptors. This would suggest that in the absence of
norBNI, Rog-µA may be constitutively active. However,
the receptor still signals robustly in response to spirado-
line (Figure 5A), so it cannot be fully active in the absence
of ligand. It is also possible that, under basal conditions,
Rog-µA has a higher than normal affinity for GRK or arres-
tin, but not the G proteins. This would result in constitu-
tive turnover – the receptor constantly cycling in and out
of the membrane – in the absence of constitutive signal-
ing. The idea that this receptor is especially sensitive to the
desensitization and internalization machinery is borne
out by the observation of extensive desensitization in
response to pretreatment with a low dose of agonist (Fig-
ure 5A). It will be interesting to investigate the physiolog-
ical consequences of this apparent constitutive
internalization and rapid desensitization in animal
models.
Although most of the C-terminal sequence of Rog-µA is
derived from the MOR, the MOR does not exhibit either
constitutive turnover or abnormally low membrane
expression. There is some evidence for partial basal inter-
nalization of the similar Rog-µ receptor (Figure 4A),
although Rog-µ appears to be expressed predominantly at
the cell surface under basal conditions. Since Rog-µ and
Rog-µA differ at only five amino acids, some of those five
residues must be responsible for the increased turnover of
Rog-µA. Although phosphorylation of T394 has been
reported to be required for desensitization of the MOR
[18], subsequent reports have shown that mutating T394
to alanine facilitates the internalization and resensitiza-
tion of the receptor [27]. This suggests that phosphoryla-
tion of T394 may be a membrane retention signal and that
the T394A mutation in Rog-µA is responsible for the con-
stitutive endocytosis observed in this study. Mutagenesis
of individual amino acids in this region may allow theBMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
Page 11 of 14
(page number not for citation purposes)
identification of the specific residue(s) responsible for the
constitutive internalization of Rog-µA.
The differences in AC superactivation between our RASSLs
indicate another layer of complexity in GPCR signaling.
Previous studies suggest an inverse correlation between
the ability of an opioid receptor to undergo ligand-acti-
vated endocytosis and its ability to induce AC superactiva-
tion by chronic signaling [28]. The induction of
superactivation by Rog is consistent with this idea. Rog-µ,
which internalizes and desensitizes readily, failed to
induce any AC superactivation after chronic activation
(Figure 5B). Similarly, Rog-µA, which may undergo con-
stitutive endocytosis, did not induce AC superactivation
after chronic administration of spiradoline. However,
Rog-A, which was predicted to have enhanced superacti-
vation due to its resistance to endocytosis, had levels of
superactivation comparable to those seen with Rog. It is
possible that Rog induces maximal superactivation, and
the cell cannot respond to Rog-A signaling with any addi-
tional superactivation. Our results indicate that internali-
zation does not directly induce AC superactivation. The
dose of spiradoline (10 nM over 18 hours) used to induce
strong AC superactivation in these experiments causes
only minimal internalization of all of the receptors (Fig-
ure 5C). Moreover, there is no significant difference in
degree of internalization among the different receptor
types, although they show profound differences in super-
activation. This suggests that the cellular mechanisms
underlying AC superactivation and receptor internaliza-
tion are independent.
AC superactivation has been attributed to upregulation of
AC proteins induced by Gβγ protein subunits interacting
directly with GRK2/3 proteins [29,30]. Therefore, the
same mutations that prolong Rog-A signaling and inhibit
endocytosis may also prevent the receptor from interact-
ing with GRK2/3 proteins and subsequently activating
Gβγ-mediated signaling events. Alterations in
desensitization characteristics are unlikely to alter AC
superactivation because of the drastic differences in time
course underlying these distinct phenomena. Receptor
desensitization happens on a scale of minutes, while AC
superactivation is the result of much longer term chronic
receptor activation. Therefore, a decrease in Gi signaling
due to a more desensitized receptor is unlikely to have a
significant effect on AC superactivation over the much
longer time course used in these experiments. The addi-
tional possibility exists that altering C-terminal residues
on the RASSL could increase the ability of receptors to
couple to Go, resulting in perceived changes in AC super-
activation [31]. However, if this were the case, one would
expect to see a shift in the dose response curve for cAMP
inhibition between Rog, Rog-A, Rog-µ and Rog-µA that is
not observed in any of our experiments. Further studies
with this engineered receptor system in vivo may clarify
the complex relationship between ligand dependent
endocytosis, interaction of a GPCR C-terminus with
GRK2/3, desensitization, and superactivation of AC.
The ability of these RASSLs to induce different degrees of
AC superactivation may have important physiological
consequences in vivo. Interestingly, when a RASSL with a
C-terminus corresponding to the wild-type human KOR
was expressed at high levels in the hearts of transgenic
mice, the mice developed a lethal cardiomyopathy [32].
One possible explanation is that basal signaling of the
RASSL in mouse heart may increase Gs signaling through
AC superactivation. Gs signaling has long been associated
with heart failure, so AC superactivation may be responsi-
ble for the cardiomyopathy. Rog-µ and Rog-µA, RASSLs
that do not induce superactivation, could be used to test
this hypothesis and to study the consequences of AC
superactivation in other tissues.
Internalized opioid receptors can be either degraded or
recycled back to the membrane. The receptors that return
to the membrane are stripped of arrestin, phosphates, and
ligand, and are resensitized to ligand. Recent evidence
demonstrates that the C-terminus is crucial for directing
internalized receptors either into the degradative lyso-
somal pathway or back to the plasma membrane [27,33].
We expect that several of our engineered RASSLs should
also differ in their post-endocytotic fate.
It is likely that the complex mechanisms governing GPCR
endocytosis, recycling, desensitization and AC superacti-
vation will be regulated differently in different cell types.
The RASSLs described here exhibit similar properties in
several different mammalian cell lines we tested (rat1a,
CHO and HEK293), but their properties may change in
specific cell types or under specific physiological condi-
tions. One potentially fruitful avenue for future investiga-
tions would be to target different RASSLs to particular cell
types in vivo. This would allow a thorough investigation of
the interplay between receptor sequence and cell-type spe-
cific mechanisms of receptor regulation.
The development of a toolbox of engineered RASSLs that
differ in internalization and desensitization raises several
possibilities for future research and clinical investigations.
Growing evidence points to a link between receptor
dynamics and the potential for drugs to elicit tolerance or
dependence, especially for opioid receptors [28,34]. Here,
we present a system that allows the same drug to activate
different receptors that have small, well-defined variations
in sequence. The efficacy and potency of spiradoline is
similar for Rog, Rog-A, Rog-µ and Rog-µA (Table 1); only
the desensitization and internalization responses vary.
Specifically, agonist-induced internalization is reduced inBMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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Rog-A and enhanced in Rog-µ, while Rog-µA shows ago-
nist-independent internalization. Rog-A shows no desen-
sitization after a brief spiradoline pretreatment, while the
same treatment reduces the potency of spiradoline at Rog-
µA and reduces efficacy at Rog-µ. Longer spiradoline pre-
treatment induces normal AC superactivation at Rog-A,
but does not affect the AC response in Rog-µ or Rog-µA
cells.
A family of engineered GPCRs that do not respond to
endogenous ligands has enormous potential for selec-
tively controlling G protein signaling in specific tissues
without interfering with endogenous processes. Rog-A, a
long-signaling RASSL, has several interesting implications
for in vivo signal engineering. The basic RASSL, Ro2, shows
rapid and extensive physiological desensitization [14],
making it difficult to use in any therapeutic context where
repeated activation of the receptor would be necessary.
Rog-A, with its reduced desensitization, could allow con-
tinued physiological efficacy of repeated drug treatments.
Comparison of the regulation and signaling of Rog, Rog-
A, Rog-µ, Rog-µA, and future variants will contribute to
the growing understanding of how GPCR signals are
dynamically modulated. Study of these RASSLs in vivo will
help solidify the elusive links between the receptor amino
acid sequence, cell biology, and complex physiology.
Methods
Construction of mutant receptors
All receptors were based on the human kappa-opioid
RASSL called Ro2 [12]. The GFP-tagged version of the
RASSL has been named "Rog" for RASSL opioid with GFP
tag. Rog was made by inserting the coding sequence for
emerald GFP (Packard) at the N-terminus of the receptor,
after a FLAG tag (DYKDDDDV) and the first eight amino
acids of the RASSL. To create Rog-A, two serines and two
threonines in the C-terminal region of the receptor were
mutated to alanines (Figure 1). In the human kappa opi-
oid receptor (KOR), the mutated residues correspond to
S356A, T357A, S358A and T363A. The exact location of
those residues in our RASSL construct, and the complete
sequence of all RASSL variants can be found on our web
site http://www.ConklinLab.org. For both Rog-µ and Rog-
µA, the final 35 amino acids (345–380) of Rog were
replaced by 47 C-terminal residues from the rat mu opioid
receptor (MOR). Rog-µA contains the following addi-
tional modifications to the rat MOR C-terminus: T383A,
E388Q, E391Q, E393Q and T394A. For each receptor, a
schematic design and a C-terminal amino acid sequence
alignment is shown in Figure 1. All constructs were
sequenced to verify the mutations.
Expression of RASSLs in mammalian cells
HEK293 cells were grown in culture to 60–80% conflu-
ence and then transfected using Lipofectamine Plus (Inv-
itrogen, Carlsbad, CA). The RASSL construct contained a
cytomegalovirus promoter to drive mammalian expres-
sion, and a neomycin-resistance gene to allow selection of
stable cell lines. Experiments on transiently transfected
cells were performed approximately 48 h after transfec-
tion. To create stable cell lines, transfected cells were
selected with G418 (500 µg/ml, Invitrogen) for 10–14
days. Individual colonies showing green fluorescence
were selected and grown under maintenance doses of
G418 (250 µg/ml). Receptor expression was confirmed
visually by fluorescence microscopy, and by an enzyme-
linked immunoadsorbent assay (ELISA, see below).
Cell-surface ELISA
Cell-surface expression of receptors was confirmed by an
ELISA that detects only extracellular FLAG tag, which
labels the N terminus of all RASSLs. This assay therefore
quantifies only receptors that are in the membrane at the
time of labeling, without providing detailed localization
data about those receptors. Cells were plated at 100,000
cells/well on to 24-well plates coated with poly-d-lysine.
Cultured cells were fixed in 4% paraformaldehyde for 10
min at 4°C, washed in phosphate-buffered saline (PBS),
and then incubated in 1 µg/ml M1 anti-FLAG antibody
(Sigma, St. Louis, MO) for 1 h at room temperature. They
were washed again in PBS with 1 mM CaCl2 and incu-
bated for 30 min at room temperature in secondary anti-
body (1:1000 goat anti-mouse conjugated with
horseradish peroxidase, Biorad, Chicago, IL), then
washed three times in PBS plus CaCl2. To develop the
reaction, 0.25 ml of 2,2-azino-bis(3-ethylbenzthiazoline-
6-sulfonic acid) liquid substrate (Sigma) was added to
each well. After 15–60 min, 200 µl from each well was
transferred to a 96-well plate and the optical density was
read at 410 nm. To quantify agonist-induced internaliza-
tion, cells were treated with various doses of spiradoline
in medium for 10–120 min. The medium was removed
and the cells were fixed and processed as described above.
Vehicle treated cells on each plate were used to calculate a
"maximum" cell-surface expression for that plate. All
other treatment conditions on that plate were then nor-
malized to this maximum to determine "percent internal-
ization." Each experiment included 3–6 replicates per
condition and was repeated at least 3 times. After values
for cell-surface expression of each receptor were calculated
and normalized, receptor expression was compared using
two-way ANOVA (StatView v. 5.0, SAS Institute, Cary,
NC). For dose response studies, receptor and dose were
independent factors. For time course studies, receptor and
length of treatment were independent factors.
cAMP accumulation assay
The degree of cAMP inhibition in spiradoline-treated
HEK-293 cells transiently expressing RASSL variants was
measured with the CatchPoint cAMP ELISA kit (MolecularBMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
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Devices, Sunnyvale, CA). Cells were plated at 5 × 104/well
into 96-well plates coated with poly-d-lysine. The next
day, cells were rinsed in Krebs-Ringer bicarbonate buffer
with glucose (KRBG, Sigma). Cells were then incubated in
pre-stimulation buffer containing a phosphodiesterase
inhibitor (0.75 mM 3-isobutyl-1-methylxanthine in
KRBG buffer) for 10 min at room temperature to inhibit
cAMP degradation. cAMP production was stimulated by
the addition of 50 µM forskolin to all cells. At the same
time, various doses of spiradoline in PBS were added to
cells to establish a dose-response curve. After a 15-min
drug treatment at 37°C, the cells were lysed and cAMP
accumulation was assayed according to the CatchPoint
protocol. Inhibition of cAMP by spiradoline was deter-
mined by comparison to cells treated with forskolin
alone. For each experiment, 3–6 wells per condition were
averaged, and EC50 and percent inhibition values for each
receptor were determined by fitting curves for each inde-
pendent experiment using SOFTmax PRO v. 4.0.1 (Molec-
ular Devices). Data for 3–8 independent experiments
were averaged to determine the EC50 and maximum
cAMP inhibition for each receptor and condition. For
desensitization assays, a pretreatment dose (1 nM) of
spiradoline diluted in sterile PBS was added to the cells,
which were then incubated for 10 min at 37°C. The cells
were rinsed 4 times in KRBG and then stimulated and
assayed for cAMP as described above. AC superactivation
was determined by measuring forskolin-stimulated (10
µM) cAMP after treatment with either 10 nM spiradoline
or vehicle for 18 h. AC superactivation data were
expressed as a percent increase in forskolin-stimulated
cAMP relative to vehicle-pretreated cells expressing the
same receptor. Conditions and receptors were compared
using a two-way ANOVA with receptor and treatment con-
dition as independent factors.
Confocal microscopy
HEK293 cells stably expressing receptor constructs were
plated at a density of 500,000 cells/ml onto glass Labtek
II chamber slides (Fisher Scientific, Pittsburgh, PA) coated
with poly-d-lysine. The following day, the cells were
treated with agonist (spiradoline or dynorphin A 1–13)
for typically one hour, or antagonist (NorBNI) overnight
and briefly washed in PBS. The PBS was removed and
replaced with 1 ml of cold 4% paraformaldehyde in PBS.
The cells were fixed at room temperature for 10 min,
washed with PBS, and then mounted in Vectashield (Vec-
tor Laboratories, Burlingame, CA) under cover slips. For
confocal imaging on a Bio-Rad MRC 600 microscope, typ-
ical images were taken with a 40–60× oil immersion
objective lens, subject to 5× Kalman filtering. The micro-
scope operator was blind to both cell line and treatment
condition.
Fluorometric imaging plate reader (FLIPR) assay
All receptors tested were transiently transfected using
Lipofectamine into CHO cells in conjunction with the
chimeric G protein Gqi5 [20] in a 5:1 molar ratio of DNA.
Gqi5 is a chimeric G protein alpha subunit that has the Gαq
wild-type sequence except for the C-terminal 5 residues,
which were changed to the corresponding Gαi sequence.
This allows Gi-coupled receptors to signal through the Gq
pathway, resulting in a signal that can be detected using
calcium-sensitive reagents. The following day, the cells
were plated in a 96-well plate (50,000 cells per well) and
allowed to grow for 24 h before being incubated with the
calcium-sensitive dye fura-3 for 1 h. The assay was per-
formed as described [12] using a range of dilutions of
either spiradoline or dynorphin A 1–13 peptide (Sigma).
All experiments were performed in triplicate.
Authors' contributions
KSL and MDL created the constructs and cell lines used
here, designed and conducted the experiments; analyzed
the data; and drafted the manuscript. HHE maintained
cell lines and participated in making constructs, internali-
zation assays and confocal microscopy. BRC conceived of
the study and participated in its design and interpretation.
All authors read and approved the final manuscript.
Acknowledgements
The authors are grateful for valuable technical assistance from David Sanan 
(confocal microscopy), Jin Liao (FLIPR assay), Sam Davis (assembly of 
receptor constructs), and Taeryn Kim (ELISA assays and cell culture). We 
also thank Drs. Lennart Mucke, Nathalie Cotte, Kam Dahlquist, Supriya 
Srinivasan, Whit Tingley and Alex Zambon for their insightful discussions 
and careful reading of this manuscript. Gary Howard, Stephen Ordway and 
Bethany Taylor provided editorial assistance in revision and preparation of 
this manuscript. This work was supported by NIH HL6064 (BRC) and a 
NIDA NRSA fellowship (KSL).
References
1. Ferguson SSG: Evolving concepts in G protein-coupled recep-
tor endocytosis: The role in receptor desensitization and
signaling. Pharmacol Rev 2001, 53:1-24.
2. Paing MM, Stutts AB, Kohout TA, Lefkowitz RJ, Trejo J: β-arrestins
regulate protease-activated receptor-1 desensitization but
not internalization or down-regulation.  J Biol Chem 2002,
277:1292-1300.
3. Avidor-Reiss T, Nevo I, Levy R, Pfeuffer T, Vogel Z: Chronic opioid
treatment induces adenylyl cyclase V superactivation. J Biol
Chem 1996, 271:21309-21315.
4. Kieffer BL, Evans CJ: Opioid tolerance – In search of the holy
grail. Cell 2002, 108:587-590.
5. Borgland SL, Connor M, Osborne PB, Furness JB, Christie MJ: Opioid
agonists have different efficacy profiles for G protein activa-
tion, rapid desensitization, and endocytosis of mu-opioid
receptors. J Biol Chem 2003, 278:18776-18784.
6. Alvarez VA, Arttamangkul S, Dang V, Salem A, Whistler JL, Von Zas-
trow M, Grandy DK, Williams JT: mu-Opioid receptors: Ligand-
dependent activation of potassium conductance, desensiti-
zation, and internalization. J Neurosci 2002, 22:5769-5776.
7. Zimmer M, Palmer A, Kohler J, Klein R: EphB-ephrinB bi-direc-
tional endocytosis terminates adhesion allowing contact
mediated repulsion. Nat Cell Biol 2003, 5:869-878.Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
BMC Biology 2005, 3:3 http://www.biomedcentral.com/1741-7007/3/3
Page 14 of 14
(page number not for citation purposes)
8. Haglund K, Sigismund S, Polo S, Szymkiewicz I, Di Fiore PP, Dikic I:
Multiple monoubiquitination of RTKs is sufficient for their
endocytosis and degradation. Nat Cell Biol 2003, 5:461-466.
9. Nong Y, Huang YQ, Ju W, Kalia LV, Ahmadian G, Wang YT, Salter
MW:  Glycine binding primes NMDA receptor
internalization. Nature 2003, 422:302-307.
10. Braithwaite SP, Xia H, Malenka RC: Differential roles for NSF and
GRIP/ABP in AMPA receptor cycling. Proc Natl Acad Sci USA
2002, 99:7096-7101.
11. St John PA, Gordon H: Agonists cause endocytosis of nicotinic
acetylcholine receptors on cultured myotubes.  J Neurobiol
2001, 49:212-223.
12. Coward P, Wada HG, Falk MS, Chan SDH, Meng F, Akil H, Conklin
BR: Controlling signaling with a specifically designed Gi-cou-
pled receptor. Proc Natl Acad Sci USA 1998, 95:352-357.
13. Scearce-Levie K, Coward P, Redfern CH, Conklin BR: Engineering
receptors activated solely by synthetic ligands (RASSLs).
Trends Pharmacol Sci 2001, 22:414-420.
14. Redfern CH, Coward P, Degtyarev MY, Lee EK, Kwa AT, Hen-
nighausen L, Bujard H, Fishman GI, Conklin BR: Conditional
expression and signaling of a specifically designed Gi-coupled
receptor in transgenic mice. Nat Biotechnol 1999, 17:165-169.
15. Zhao GQ, Zhang Y, Hoon MA, Chandrashekar J, Erlenbach I, Ryba NJ,
Zuker CS: The receptors for mammalian sweet and umami
taste. Cell 2003, 115:255-266.
16. Capeyrou R, Riond J, Corbani M, Lepage J-F, Bertin B, Emorine LJ:
Agonist-induced signaling and trafficking of the µ-opioid
receptor: Role of serine and threonine residues in the third
cytoplasmic loop and C-terminal domain.  FEBS Lett 1997,
415:200-205.
17. El Kouhen R, Burd AL, Erickson-Herbrandson LJ, Chang C-Y, Law P-
Y, Loh HH: Phosphorylation of Ser363, Thr370, and Ser375 resi-
dues within the carboxyl tail differentially regulates µ-opioid
receptor internalization. J Biol Chem 2001, 276:12774-12780.
18. Pak Y, O'Dowd BF, George SR: Agonist-induced desensitization
of the µ opioid receptor is determined by threonine 394 pre-
ceded by acidic amino acids in the COOH-terminal tail. J Biol
Chem 1997, 272:24961-24965.
19. Schulz R, Wehmeyer A, Schulz K: Visualizing preference of G
protein-coupled receptor kinase 3 for the process of κ-opioid
receptor sequestration. Mol Pharmacol 2002, 61:1444-1452.
20. Conklin BR, Farfel Z, Lustig KD, Julius D, Bourne HR: Substitution
of three amino acids switches receptor specificity of Gqα to
that of Giα. Nature 1993, 363:274-276.
21. Petäjä-Repo UE, Hogue M, Bhalla S, Laperrière A, Morello J-P, Bouvier
M: Ligands act as pharmacological chaperones and increase
the efficiency of δ opioid receptor maturation. EMBO J 2002,
21:1628-1637.
22. Morello J-P, Salahpour A, Laperrière A, Bernier V, Arthus M-F, Lon-
ergan M, Petäjä-Repo U, Angers S, Morin D, Bichet DG, Bouvier M:
Pharmacological chaperones rescue cell-surface expression
and function of misfolded V2 vasopressin receptor mutants.
J Clin Invest 2000, 105:887-895.
23. McLaughlin JP, Xu M, Mackie K, Chavkin C: Phosphorylation of a
carboxy-terminal serine within the kappa opioid receptor
produces desensitization and internalization. J Biol Chem 2003,
278:34631-34640.
24. Bouvier M, Hausdorff WP, De Blasi D, O'Dowd BF, Kobilka BK,
Caron MG, Lefkowitz RJ: Removal of phosphorylation sites
from the β2-adrenergic receptor delays onset of agonist-pro-
moted desensitization. Nature 1988, 333:370-373.
25. Ferguson SSG, Ménard L, Barak LS, Koch WJ, Colapietro A-M, Caron
MG: Role of phosphorylation in agonist-promoted β2-adren-
ergic receptor sequestration.  J Biol Chem 1995,
270:24782-24789.
26. Qiu Y, Law PY, Loh HH: µ-opioid receptor desensitization: Role
of receptor phosphorylation, internalization and
representation. J Biol Chem 2003, 278:36733-36739.
27. Wolf R, Koch T, Schulz S, Klutzny M, Schröder H, Raulf E, Bühling F,
Höllt V: Replacement of threonine 394 by alanine facilitates
internalization and resensitization of the rat µ opiod
receptor. Mol Pharmacol 1999, 55:263-268.
28. Finn AK, Whistler JL: Endocytosis of the mu opioid receptor
reduces tolerance and a cellular hallmark of opiate
withdrawal. Neuron 2001, 32:829-839.
29. Chakrabarti S, Oppermann M, Gintzler AR: Chronic morphine
induces the concomitant phosphorylation and altered asso-
ciation of multiple signaling proteins: A novel mechanism for
modulating cell signaling.  Proc Natl Acad Sci USA 2001,
98:4209-4214.
30. Pitcher JA, Freedman NJ, Lefkowitz RJ: G protein-coupled recep-
tor kinases. Annu Rev Biochem 1998, 67:653-692.
31. Watts VJ: Molecular mechanisms for heterologous sensitiza-
tion of adenylate cyclase. J Pharmacol Exp Ther 2002, 302:1-7.
32. Redfern CH, Degtyarev MY, Kwa AT, Salomonis N, Cotte N, Nanev-
icz T, Fidelman N, Desai K, Vranizan K, Lee EK, Coward P, Shah N,
Warrington JA, Fishman GI, Bernstein D, Baker AJ, Conklin BR: Con-
ditional expression of a Gi-coupled receptor causes ventricu-
lar conduction delay and a lethal cardiomyopathy. Proc Natl
Acad Sci USA 2000, 97:4826-4831.
33. Whistler JL, Enquist J, Marley A, Fong J, Gladher F, Tsuruda P, Murray
SR, von Zastrow M: Modulation of postendocytic sorting of G
protein-coupled receptors. Science 2002, 297:615-620.
34. Bohn LM, Gainetdinov RR, Lin FT, Lefkowitz RJ, Caron MG: Mu-opi-
oid receptor desensitization by beta-arrestin-2 determines
morphine tolerance but not dependence.  Nature 2000,
408:720-723.